QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
On April6, 2017, Quintiles IMS Holdings, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders. As of February15, 2017,
the record date for the meeting, there were 235,874,761 shares of
common stock outstanding and entitled to vote on all matters. At
the meeting, stockholders voted on the following items:
Proposal No. 1 The following nominees were
elected by majority vote to serve on the Board of Directors as
Class I directors:
| For | Withhold | Broker Non-Vote | ||||||||||
|
Jonathan J. Coslet |
210,919,958 | 10,263,291 | 5,304,231 | |||||||||
|
Michael J. Evanisko |
217,209,552 | 3,973,697 | 5,304,231 | |||||||||
|
Dennis B. Gillings, CBE |
208,866,502 | 12,316,747 | 5,304,231 | |||||||||
|
Ronald A. Rittenmeyer |
215,746,249 | 5,437,000 | 5,304,231 |
Proposal No.2 An advisory vote on executive
compensation was approved.
|
For |
Against |
Abstain |
Broker Non-Vote |
|||
|
185,663,844 |
25,059,035 | 10,460,370 | 5,304,231 |
Proposal No.3 An advisory vote on the frequency
of advisory votes on the compensation of the Companys named
executive officers every three years was approved.
|
1 Year |
2 Years |
3 Years |
Abstain |
Broker Non-Vote |
||||
|
106,087,600 |
118,983 | 114,905,222 | 71,444 | 5,304,231 |
Proposal No.4 The proposal for the adoption of
the Quintiles IMS Holdings, Inc. 2017 Stock and Incentive Award
Plan was approved.
|
For |
Against |
Abstain |
Broker Non-Vote |
|||
|
217,040,480 |
4,057,118 | 85,651 | 5,304,231 |
Proposal No.5 The appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the year ending December31, 2017 was
ratified.
|
For |
Against |
Abstain |
Broker Non-Vote |
|||
|
225,550,513 |
860,814 | 76,153 |
About QUINTILES IMS HOLDINGS, INC. (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions. QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Recent Trading Information
QUINTILES IMS HOLDINGS, INC. (NYSE:Q) closed its last trading session up +1.10 at 79.33 with 1,143,649 shares trading hands.
